Objective: To report the initial experiences with the 25-gauge transconjunctival sutureless vitrectomy (TSV) system, including intraoperative and postoperative problems. Methods: We retrospectively reviewed the medical records and surgical videotapes of 50 consecutive patients who underwent vitrectomy performed by one surgeon using the TSV system. Results: Intraoperatively, we encountered such problems as difficulty in inserting the microcannula, which led to deformity, instability of the microcannula, self-disconnection of the infusion tip and resultant lens damage, and conversion to 20-gauge conventional vitrectomy. Postoperatively, there were 8 cases with hypotony (IOP < 6 mm Hg) on day 1, 6 cases with elevated IOP, and 3 cases with retinal detachment during follow-up. Conclusion: Though certain problems exist during and after surgeries using TSV, this system is both convenient and safe for various vitreoretinal procedures.

1.
Machemer R, Buettner H, Norton EW, Parel JM: Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 1971;75:813–820.
2.
Fujii GY, de Juan E, Humayun MS, et al: A new instrument system for transconjunctival sutureless vitrectomy surgery. Ophthalmology 2002;109:1807–1813.
3.
Fujii GY, de Juan E, Humayun MS, et al: Initial experience using the transconjunctival sutureless vitrectomy system for vitrectomy surgery. Ophthalmology 2002;109:1814–1820.
4.
Chen JC: Sutureless pars plana vitrectomy through self-sealing sclerotomies. Arch Ophthalmol 1996;114:1273–1275.
5.
Milibak T, Suveges I: Complications of sutureless pars plana vitrectomy through self-sealing sclerotomies. Arch Opthalmol 1998;116:119.
6.
Kwok AK, Tham CC, Lam DS, Li M, Chen JC: Modified sutureless sclerotomies in pars plana vitrectomy. Am J Ophthalmol 1999;127:731–733.
7.
Jackson T: Modified sutureless sclerotomies in pars plana vitrectomy. Am J Ophthalmol 2000;129:116–117.
8.
Rahman R, Rosen PH, Riddell C, Towler H: Self-sealing sclerotomies for sutureless pars plana vitrectomy. Ophthalmic Surg Lasers 2000;31:462–466.
9.
Hilton GF, Josepherg RG, Halperin LS, et al: Office-based sutureless transconjunctival pars plana vitrectomy. Retina 2002;22:725–732.
10.
Lakhanpal RR, Humayun MS, de Juan E, et al: Ophthalmology 2005;112:817–824.
11.
Ibarra MS, Hermel M, Prenner JL, Hassan TS: Long-term outcomes of transconjunctival sutureless 25-gauge vitrectomy. Am J Opthalmol 2005;139:831–836.
12.
Lam DSC, Yuen CYF, Tam BSM, Cheung BTO, Chan W: Sutureless vitrectomy system. Ophthalmology 2003;110:2428–2429.
13.
Cho YJ, Lee JM, Kim SS: Vitreoretinal surgery using transconjunctival sutureless vitrectomy. Yonsei Med J 2004;45:615–620.
14.
Inoue M, Noda K, Ishida S, Nagai N, Imamura Y, Oguchi Y: Intraoperative breakage of a 25-gauge vitreous cutter. Am J Ophthalmol 2004;138:867–869.
15.
Liu DTL, Chan CKM, Fan DSP, Lam SW, Lam DSC, Chan WM: Choroidal folds after 25 gauge transconjunctival sutureless vitrectomy. Eye 2005;19:825–827.
16.
Meyer CH, Rodrigues EB, Schmidt JC, Horle S, Kroll P: Sutureless vitrectomy system. Ophthalmology 2003;110:2427–2428.
17.
Taylor SR, Aylward GW: Endophthalmitis following 25-gauge vitrectomy. Eye 2005;19:1228–1229.
18.
Han DP, Lewis H, Lambrou FH, et al: Mechanisms of intraocular pressure elevation after pars plana vitrectomy. Ophthalmology 1986;96:1357–1362.
19.
Ando F: Intraocular hypertension resulting from papillary block by silicone oil. Am J Ophthalmol 1985;99:87–88.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.